Trial Profile
An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Surufatinib (Primary)
- Indications Intestinal cancer; Lung cancer; Neuroendocrine tumours
- Focus Therapeutic Use
- Sponsors HUTCHMED
- 08 Feb 2024 Planned primary completion date changed from 15 Sep 2023 to 15 Sep 2024.
- 01 Apr 2023 This trial has been Completed in Belgium, According to European Clinical Trials Database record.
- 23 Feb 2023 This trial has been suspended in Spain, according to European Clinical Trials Database record.